NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a proprietary platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries (SCI) intranasally.
TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a Toronto-listed biopharmaceutical company, is developing ExoPTEN, a proprietary platform for producing and loading exosomes with pharmaceutical cargo targeting spinal cord injuries (SCI) intranasally.
NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes.
This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency.
Exosomes are nanocarriers with the unique ability to carry “cargo” to target specific cells and inflamed tissue, while navigating extracellular spaces and penetrating cell membranes. Exosomes loaded with therapeutic pharmaceutical cargo (ExoTherapy) are a highly promising drug delivery platform.
ExoPTEN, minimally invasive therapy for spinal cord injuries
ExoPTEN, the company’s flagship product, is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cords. It has shown promising results in laboratory studies for reversing paralysis in rats.
NurExone’s innovative and proprietary technology has been in development in the Technion, Haifa and Tel Aviv University, two of the most prominent research institutes in Israel for over ten years.
With a global market that is projected to reach $5.2 billion by 2027 divided between $2.9bn for acute SCI and $2.3bn for Exosome based technology (Diagnostic and Therapeutic) and the lack of comparable therapies currently available, NurExone’s ExoTherapy platform has the potential to significantly improve patient outcomes and change the game for SCI treatment. The company is committed to working first with the spinal cord injury community, to bring this groundbreaking technology to those who need it most.
The company recently received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application NO. 17/042,441, which covers and protects its ExoPTEN technology, drug composition, and methods for non-invasive intranasal administration of exosome-based treatment. This solidifies the company’s intellectual property portfolio and positions it to be at the forefront of this exciting field.
NurExone’s management team, led by CEO Dr. Lior Shaltiel, is composed of experienced professionals, with a track record of success in the pharmaceutical industry. Additionally, its scientific advisory board includes leading experts in the fields of drug delivery and CNS therapeutics.
“We believe that our biologically-guided exosome technology has the potential to significantly improve patient outcomes and revolutionize the field of spinal cord injury treatment,” explained Shaltiel.
The company is currently working with a team of world-class experts in the field, including Dr. Lyora Aharonov, an expert in biological research who serves as the R&D Director, and an advisory board of scientists led by Prof. Shulamit Levenberg, who has received several prizes, including the Krill Prize for excellence in scientific research, and Dr. Nahshon Knoller, head of the neurosurgery department in the largest hospital in Israel, who led their clinical SCI studies.
“At NurExone, our vision is to revolutionize recovery from trauma-induced central nervous system damage, by the regeneration and ‘rewiring’ of neurons, and to improve the quality of life for patients suffering from these injuries. We are driven by a passion to make a meaningful impact on the world and are dedicated to bringing our cutting-edge technology to patients in need,” Shaltiel added.
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements, including statements about the Company’s future plans and intellectual property, the scientific, development and IP activities to be carried out by the Company, future potential manufacturing and marketing activities and the treatment of certain conditions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, or “potential”, or the negative, or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company’s intellectual property and dependence on the Company’s strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For additional information: https://nurexone.com/investors/ Or contact: Investor Relations Phone: +1 905-347-5569 Email: IR@nurexone.com
